Helen & Robert Appel Alzheimer’s Disease Research Institute

Publications

Found 444 results
[ Author(Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
N
Netzer WJ, Sinha A, Ghias M, Chang E, Gindinova K, Mui E, Seo J-S, Sinha SC.  2024.  Stretching the structural envelope of imatinib to reduce β-amyloid production by modulating both β- and γ-secretase cleavages of APP.. Front Chem. 12:1381205.
Naseri NN, Xu T, Chantarawong S, Patrie SM, Kelleher NL, Sharma M, Shalem O, Rhoades E.  2025.  Specific Combinations of Physiological Tau Phosphorylation Regulate Tau-Microtubule Interactions in Developing Neurons.. bioRxiv.
Naseri NN, Wang H, Guo J, Sharma M, Luo W.  2019.  The complexity of tau in Alzheimer's disease.. Neurosci Lett. 705:183-194.
Naseri N, Sharma M, Velinov M.  2020.  Autosomal dominant neuronal ceroid lipofuscinosis: Clinical features and molecular basis.. Clin Genet.
Naseri NN, Ergel B, Kharel P, Na Y, Huang Q, Huang R, Dolzhanskaya N, Burré J, Velinov MT, Sharma M.  2020.  Aggregation of mutant cysteine string protein-α via Fe-S cluster binding is mitigated by iron chelators.. Nat Struct Mol Biol. 27(2):192-201.
Naguib S, Lopez-Lee C, Torres ERuth, Lee S-I, Zhu J, Zhu D, Ye P, Norman K, Zhao M, Wong MYing et al..  2025.  APOE3-R136S mutation confers resilience against tau pathology via cGAS-STING-IFN inhibition.. bioRxiv.
Naguib S, Lopez-Lee C, Torres ERuth, Lee S-I, Zhu J, Zhu D, Ye P, Norman K, Zhao M, Wong MYing et al..  2025.  The R136S mutation in the APOE3 gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway.. Immunity. 58(8):1931-1947.e9.
M
Murava ALicht, Meadows S, Palaguachi F, Song SC, Bram Y, Zhou C, Schwartz RE, Froemke RC, Orr AL, Orr AG.  2021.  Dementia-linked TDP-43 dysregulation in astrocytes impairs memory, antiviral signaling, and chemokine-mediated astrocytic-neuronal interactions.. Alzheimers Dement. 17 Suppl 2:e058562.
Mullasseril P, Hansen KB, Vance KM, Ogden KK, Yuan H, Kurtkaya NL, Santangelo R, Orr AG, Le P, Vellano KM et al..  2010.  A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors.. Nat Commun. 1:90.
Mukherjee K, Sharma M, Urlaub H, Bourenkov GP, Jahn R, Südhof TC, Wahl MC.  2008.  CASK Functions as a Mg2+-independent neurexin kinase.. Cell. 133(2):328-39.
Mukherjee K, Sharma M, Jahn R, Wahl MC, Südhof TC.  2010.  Evolution of CASK into a Mg2+-sensitive kinase.. Sci Signal. 3(119):ra33.
Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L et al..  2006.  Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease.. Neuron. 51(6):703-14.
Muchardt C, Seeler JS, Nirula A, Gong S, Gaynor R.  1992.  Transcription factor AP-2 activates gene expression of HTLV-I.. EMBO J. 11(7):2573-81.
Mossa A, Dierdorff L, Lukin J, Garcia-Forn M, Wang W, Mamashli F, Park Y, Fiorenzani C, Akpinar Z, Kamps J et al..  2025.  Sex-specific perturbations of neuronal development caused by mutations in the autism risk gene DDX3X.. Nat Commun. 16(1):4512.
Morciano M, Burré J, Corvey C, Karas M, Zimmermann H, Volknandt W.  2005.  Immunoisolation of two synaptic vesicle pools from synaptosomes: a proteomics analysis.. J Neurochem. 95(6):1732-45.
Möller T, Bard F, Bhattacharya A, Biber K, Campbell B, Dale E, Eder C, Gan L, Garden GA, Hughes ZA et al..  2016.  Critical data-based re-evaluation of minocycline as a putative specific microglia inhibitor.. Glia. 64(10):1788-94.
S Minami S, Min S-W, Krabbe G, Wang C, Zhou Y, Asgarov R, Li Y, Martens LH, Elia LP, Ward ME et al..  2014.  Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models.. Nat Med. 20(10):1157-64.
S Minami S, Shen V, Le D, Krabbe G, Asgarov R, Perez-Celajes L, Lee C-H, Li J, Donnelly-Roberts D, Gan L.  2015.  Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with α7 nicotinic acetylcholine receptor agonists.. Biochem Pharmacol. 97(4):454-462.
S Minami S, Sun B, Popat K, Kauppinen T, Pleiss M, Zhou Y, Ward ME, Floreancig P, Mucke L, Desai T et al..  2012.  Selective targeting of microglia by quantum dots.. J Neuroinflammation. 9:22.
Min S-W, Sohn PD, Cho S-H, Swanson RA, Gan L.  2013.  Sirtuins in neurodegenerative diseases: an update on potential mechanisms.. Front Aging Neurosci. 5:53.
Min S-W, Cho S-H, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C et al..  2010.  Acetylation of tau inhibits its degradation and contributes to tauopathy.. Neuron. 67(6):953-66.
Min S-W, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, S Minami S, Defensor E, Mok SAnn et al..  2015.  Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.. Nat Med. 21(10):1154-62.
Min S-W, Sohn PDongmin, Li Y, Devidze N, Johnson JR, Krogan NJ, Masliah E, Mok S-A, Gestwicki JE, Gan L.  2018.  SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.. J Neurosci. 38(15):3680-3688.
Medrihan L, Umschweif G, Sinha A, Reed S, Lee J, Gindinova K, Sinha SC, Greengard P, Sagi Y.  2020.  Reduced Kv3.1 Activity in Dentate Gyrus Parvalbumin Cells Induces Vulnerability to Depression.. Biol Psychiatry. 88(5):405-414.
Mecozzi VJ, Berman DE, Simoes S, Vetanovetz C, Awal MR, Patel VM, Schneider RT, Petsko GA, Ringe D, Small SA.  2014.  Pharmacological chaperones stabilize retromer to limit APP processing.. Nat Chem Biol. 10(6):443-9.